Centene Corporation to Acquire Majority Stake in Fidelis SecureCare of Michigan

ST. LOUIS, Dec. 18, 2013 /PRNewswire/ — Centene Corporation (NYSE: CNC) (“Centene”) announced today that it has signed a definitive agreement to purchase a majority stake in Fidelis SecureCare of Michigan, Inc. (“Fidelis SecureCare”), a […]

Read On ›

MSDC Presents Phase 2a Clinical Trial Results at the 14th International Conference on Alzheimer’s Drug Discovery

 KALAMAZOO, Mich., /Sept. 9, 2013 – Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September […]

Read On ›

Fidelis Seniorcare Closes $20.5 Million Equity Financing

Schaumburg, Illinois – May 20, 2013 – Fidelis SeniorCare, Inc., a managed care company that administers Medicare Advantage Special Needs Plans to dual eligible and individuals living in long-term care facilities, announced the completion of […]

Read On ›

Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation

KALAMAZOO, Mich., Feb. 7, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct preclinical research on […]

Read On ›

Metabolic Solutions Development Company Announces Publication of Phase 2b Data in Clinical Pharmacology & Therapeutics

KALAMAZOO, Mich., Jan. 24, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company’s prototype insulin sensitizer in patients diagnosed with type 2 […]

Read On ›

NeoChord receives CE marking for DS1000 mitral valve repair device and plans first enrollments in TACT Registry for Q1 2013.

Initial registry training and proctoring to be provided by Leipzig Heart Center, Mayo Clinic and University of Pittsburgh Medical Center. TACT Trial results, recently reported at TCT and EACTS, show good safety and efficacy for […]

Read On ›